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Abstract 
Review on t(10;11)(q22;q23) KMT2A/TET1, with 
data on clinics, and the genes implicated. 
Clinics and pathology 
Disease 
Acute myeloid leukemia (AML), B-cell precursor 
acute lymphoblastic leukemia (ALL), T-cell 
lymphoblastic lymphoma 
Phenotype/cell stem origin 
Described in subtypes AML-M2, -M4 and -M5. 
Cell lineage dysplasia may be associated.  
Described also in 2 B-ALL and one case of T-cell 
lymphoblastic lymphoma with a subsequent 
transformation to AML. 
Epidemiology 
Described in 14 cases in the literature, mainly 
adults and 2 children (8 men, 5 women, 1 
unknown) median age of 39 years (range 1 month 
to 67 years). 
Frequency estimated at 0.3 % of MLL-rearranged 
acute leukemia cases (5 out 1590) (Lee et al., 
2013). 
Prognosis 
Undetermined, possibly intermediate. On the 8 of 
14 patients with available clinical outcomes, 7 had 
a complete remission.  
6 patients died at an average of 16 months after 
initial diagnosis. 
 
 
Cytogenetics 
Cytogenetics morphological 
Easy to detect, evident 10q- and 11q+ derivatives. 
Cytogenetics molecular 
Commercial dual color MLL/KMT2A FISH probes 
are splitted by the translocation. 10q22 breakpoint 
may be detected with RP11-119F7 BAC probe or 
using RP11-9E13 and RP11-314J18 BACs 
(separation of the two BACs with the 
t(10;11)(q22;q23)). 
Additional anomalies 
5/11 caryotypes available have the t(10;11) as sole 
chromosomal abnormality. 4/11 have one more 
chromosomal abnormality (+21, del(6)p(21), 
del(5)(q15), add(13)(p11) or 
der(6)t(6;?9)(p22;?q21) in 2 different clones with 
the t(10;11)); one case was hyperdiploid with 51 
chromosomes; one case had complex caryotype. 
Genes involved and 
proteins 
KMT2A 
Location 
11q23 
Note 
KMT2A is also called MLL (mixed-lineage 
leukemia or myeloid-lymphoid leukaemia), ALL-1 
or HRX. 
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A. t(10;11)(q22;q23) in RHG banding. B. The same with GTG banding. 
 
 
A. FISH on metaphase (inverted DAPI) using RP11-9E13 and RP11-314J18 BACs showing the separation of the two probes in 
the t(10;11)(q22;q23). B. Focus on chromosomes 10 and 11 and derivative chromosomes (inverted DAPI) from the t(10;11) with 
the same BACs. 
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DNA/RNA 
36 exons, multiple transcripts 13-15 kb. 
 
Protein 
430 kDA, contains two DNA binding motifs (a AT 
hook and a CXXC domain), a DNA methyl 
transferase motif, a bromodomain; transcriptional 
regulatory factor involved in maintenance of Hox 
gene expression during embryogenesis and during 
the process of haematopoietic progenitors 
expansion and differentiation. 
TET1 
Location 
10q22 
Note 
TET1 is also called LCX (leukemia-associated 
protein with a CXXC domain) or CXXC6 (CXXC 
finger 6). 
DNA/RNA 
8497 bp representing the whole coding sequence. 
Contains 12 exons. Contains 3 bipartite nuclear 
localization sites, 1 alpha helice coiled-coil region 
and 1 cysteine rich domain with high level 
homology with a CXXC DNA binding site. 
Protein 
Predicted size of 2136 amino acids, expression 
restricted to some fetal tissues, mainly lung, heart 
and brain; not expressed in hematopoietic tissues, 
except in spleen; unknown function. 
TET family enzymes convert 5-methylcytosine 
(5mC) to 5-hydroxymethylcytosine (5hmC). Key 
role in active DNA demethylation. TET1 and 
TET2: key enzymes responsible for the presence of 
5hmC in mouse embryonic stem cells (ESCs). 
TET1: regulates the lineage differentiation potential 
of ESCs. TET1 interacts physically with NANOG, 
synergistically enhancing the efficiency of NANOG 
in somatic cell reprogramming. NANOG/TET1 co-
occupy genomic loci of genes associated with both 
maintenance of pluripotency and lineage 
commitment in embryonic stem cells, and may 
deposit 5hmC to target genes before the 
establishment of pluripotency. Taken together, 
these observations suggest a possible mechanism 
for the lineage switch observed in one of the 14 
cases. (Ittel et al., 2013). 
TET1 significantly up-regulated in MLL-rearranged 
leukemia. TET1: direct target gene of MLL-fusion 
proteins. MLL fusions bind to the promoter region 
of TET1 and promote its expression directly in both 
human and mouse hematopoietic stem/progenitor 
cells, cumulating in a global increase of 5hmC. 
Briefly, MLL-fusion proteins bind directly to the 
Tet1 locus. Consequently this promote its 
expression and the increased expression of Tet1  
(and the corresponding global increase of 5hmC) 
cooperates with MLL fusions in orchestrating the 
transcriptional activation of their cotargets.  
The main critical oncogenic cotargets described are 
HOXA9, MEIS1 and PBX3.  
The Hoxa9/Meis1/Pbx3 signaling cascade promotes 
cell proliferation and inhibits apoptosis/cell 
differentiation, thereby leading to cell 
transformation and leukemogenesis. (Huang et al., 
2013). 
Result of the chromosomal 
anomaly 
Hybrid gene 
Description 
Transcripts from the 5' MLL-LCX 3' fusion gene on 
der(11) are expressed; transcripts from the 5' LCX-
MLL 3' counterpart are not detected. 
Breakpoints in the MLL gene are located between 
intron 6 and exon 11. 
All genomic breakpoints within the TET1 gene 
were identified in an approximately 17 kb genomic 
region flanked by TET1 exons 8 and 12.  
Most characterized breakpoints (5 of 7 cases) were 
mapped to intron 8. 
Fusion protein 
Description 
Predicted molecular weight of 204.4 kDa. 
Oncogenesis 
Unknown; the alpha helice coiled-coil region 
retained at the COOH extremity might be involved 
in the leukemogenesis. 
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